Lisinopril Market Size, Share, Statistics, Latest Trends, Segmentation And Forecast to 2033
Global lisinopril market size is expected to reach $2.26 Bn by 2028 at a rate of 6.4%, segmented as by brand, zestoretic, prinivil, zestril, other brands
Share this Post to earn Money ( Upto ₹100 per 1000 Views )
![Lisinopril Market Size, Share, Statistics, Latest Trends, Segmentation And Forecast to 2033](https://blog.rackons.in/uploads/images/202408/image_750x_66d195ac84c67.jpg)
Overview and Scope
The lisinopril market consists of sales of prinivil, qbrelis, zestoretic, zestril and apo-lisinopril. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Sizing and Forecast
The lisinopril market size has grown strongly in recent years. It will grow from $1.66 billion in 2023 to $1.76 billion in 2024 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to increased accessibility, lifestyle shifts, increased screening programs, increased accessibility of generic lisinopril, and increased patient adherence.
The lisinopril market size is expected to see strong growth in the next few years. It will grow to $2.26 billion in 2028 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to rising prevalence of hypertension and cardiovascular diseases, generic versions and cost-effectiveness, growing awareness and early diagnosis, growing demand for effective treatments, and aging population. Major trends in the forecast period include innovations in drug delivery, need for enhanced and patient-centric drug delivery approaches, demand for cost-effective solutions, demand for effective treatments for heart failure, and demand for effective treatments for diabetic kidney disease.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/lisinopril-global-market-report
Segmentation & Regional Insights
The lisinopril market covered in this report is segmented –
1) By Brand: Zestoretic, Prinivil, Zestril, Other Brands
2) By Disease: Hypertension, Heart Failure, Heart Attack, Strokes, Diabetic Kidney Disease, Other Diseases
3) By Dosage: Tablet, Liquid, Other Dosages
4) By Population Type: Children, Adults
5) By End-Users: Hospitals, Specialty Clinics, Other End-Users
North America was the largest region in the lisinopril market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lisinopril market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16465&type=smp
Major Driver Impacting Market Growth
The growing prevalence of cardiovascular diseases is expected to propel the growth of the lisinopril market going forward. Cardiovascular diseases (CVDs) encompass a range of disorders affecting the heart and blood vessels. The growing prevalence of cardiovascular diseases can be attributed to several factors, such as population growth and aging, risk factors, and lack of implementation of proven prevention and treatment strategies. Lisinopril helps manage cardiovascular diseases primarily through its ability to lower blood pressure and reduce the strain on the heart and kidneys. This inhibits the production of angiotensin II, facilitates the dilation of blood vessels, reduces blood volume, and protects organs from damage. For instance, in May 2022, according to the Centers for Disease Control and Prevention, a US-based governmental organization, the prevalence of coronary heart disease among adults aged 18 and over stood at 4.6% in 2020, experiencing a slight uptick to 4.9% in 2021. Therefore, the growing prevalence of cardiovascular diseases is driving the growth of the lisinopril market.
Growing Hypertension Prevalence To Drive Expansion Of The Lisinopril Market
The increasing prevalence of hypertension is expected to propel the growth of the lisinopril market going forward. Hypertension, commonly known as high blood pressure, is a medical condition in which the force of the blood against the walls of the arteries is consistently too high. The rising prevalence of hypertension is due to an unhealthy diet, a sedentary lifestyle, an aging population, and long-term stress. Lisinopril is an effective medication for managing hypertension by blocking the formation of angiotensin II, leading to the relaxation of blood vessels, reduced blood volume, and lower blood pressure. For instance, in March 2023, The World Health Organization, a Switzerland-based health organization, around 1.28 billion adults aged 30–79 years worldwide had hypertension in 2023. Therefore, the increasing prevalence of hypertension drives the lisinopril market.
Key Industry Players
Major companies operating in the lisinopril market are Merck & Co. Inc., Pfizer Inc., AbbVie Inc. , AstraZeneca Plc, Vitaris Inc., Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc., Hetero Ltd., Sun Pharmaceutical Industries Limited, Aurobindo Pharma Ltd., Cipla Inc., Hikma Pharmaceutical Plc, Apotex Inc., Amneal Pharmaceutical Inc., Lupin Ltd., Zhejiang Huahai Pharmaceutical Co. Ltd., Metrochem API Private Limited , Calyx Chemicals & Pharmaceuticals Limited, Farmhispania Group, Zydus Cadila Healthcare Ltd., Qingdao Qingmei Biotech Co. Ltd., LGM Pharma LLC, Amara Labs Pvt., Sms Lifesciences
The lisinopril market report table of contents includes:
1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
…………
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model